Wells Fargo
MLYS icon

Wells Fargo’s Mineralys Therapeutics MLYS Stock Holding History

Wells Fargo’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$707K Sell
26,081
-30,675
-54% -$900K ﹤0.01% 3952
2025
Q4 		$2.06M Buy
56,756
+26,702
+89% +$1.07M ﹤0.01% 3407
2025
Q3 		$1.14M Sell
30,054
-1,703
-5% -$36.8K ﹤0.01% 3728
2025
Q2 		$430K Buy
31,757
+4,874
+18% +$70.6K ﹤0.01% 4253
2025
Q1 		$427K Buy
26,883
+3,169
+13% +$36.5K ﹤0.01% 4209
2024
Q4 		$292K Buy
23,714
+3,802
+19% +$49.7K ﹤0.01% 4549
2024
Q3 		$241K Buy
19,912
+221
+1% +$2.67K ﹤0.01% 4457
2024
Q2 		$230K Buy
19,691
+5,268
+37% +$66.3K ﹤0.01% 4428
2024
Q1 		$186K Buy
14,423
+6,405
+80% +$79.1K ﹤0.01% 4513
2023
Q4 		$69K Buy
8,018
+3,083
+62% +$24.2K ﹤0.01% 5130
2023
Q3 		$46.9K Sell
4,935
-1,388
-22% -$18.1K ﹤0.01% 5213
2023
Q2 		$108K Buy
6,323
+3,987
+171% +$59.6K ﹤0.01% 4989
2023
Q1 		$36.6K Buy
+2,336
New +$39.3K ﹤0.01% 5333

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Wells Fargo's MLYS Position: Q1 2026 in Review

Wells Fargo reduced its Mineralys Therapeutics (MLYS) stake by 54% in Q1 2026, selling an estimated $900K and leaving 26,081 shares worth $707K. The position accounts for ﹤0.01% of the portfolio, ranked #3952.

Wells Fargo first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.06M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Wells Fargo held 26,081 shares of Mineralys Therapeutics worth $707K as of Q1 2026.
  • Wells Fargo sold 30,675 Mineralys Therapeutics shares in Q1 2026, an estimated $900K.
  • Mineralys Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3952 holding.
  • Wells Fargo first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Wells Fargo's Mineralys Therapeutics position peaked at $2.06M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.